用户名  找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Biosimilars; A New Generation of Jean-Louis Prugnaud,Jean-Hugues Trouvin Book 2013 Springer-Verlag France 2013 Biomedicine.Biosimilars.Cos

[复制链接]
查看: 6312|回复: 35
发表于 2025-3-21 17:14:43 | 显示全部楼层 |阅读模式
期刊全称Biosimilars
期刊简称A New Generation of
影响因子2023Jean-Louis Prugnaud,Jean-Hugues Trouvin
视频video
发行地址Analysis of the complete legal and regulatory framework.Approach of the context of copies of biology and biotechnology drugs.Details the registration conditions.Analysis of these drugs’ marketing (dru
图书封面Titlebook: Biosimilars; A New Generation of  Jean-Louis Prugnaud,Jean-Hugues Trouvin Book 2013 Springer-Verlag France 2013 Biomedicine.Biosimilars.Cos
影响因子.Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the “generic rule” valid for small chemical entities.. .In response, a dedicated regulation was issued in the European Union. It is based on the concept of “biological medicinal products similar to a biological reference product”, or “biosimilars”. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature.. .This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products wi
Pindex Book 2013
The information of publication is updating

书目名称Biosimilars影响因子(影响力)




书目名称Biosimilars影响因子(影响力)学科排名




书目名称Biosimilars网络公开度




书目名称Biosimilars网络公开度学科排名




书目名称Biosimilars被引频次




书目名称Biosimilars被引频次学科排名




书目名称Biosimilars年度引用




书目名称Biosimilars年度引用学科排名




书目名称Biosimilars读者反馈




书目名称Biosimilars读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:41:52 | 显示全部楼层
Book 2013 other issues, such as cost management and international nomenclature.. .This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products wi
发表于 2025-3-22 03:06:43 | 显示全部楼层
,Biologicals’ Characteristics,his complexity’s consequence resides in the analytical techniques for the study of various structural aspects of the molecule population of interest. Powerful physico-chemical and biological methods have to be used in order to globally apprehend the molecules tridimensional integrity and ensure a th
发表于 2025-3-22 06:49:21 | 显示全部楼层
From the Biosimilar Concept to the Marketing Authorisation,adequate to evidence a biosimilar’s quality, safety and efficacy, due to the complexity of the products themselves but also of their production processes. The registration of biological products’ copies has been made possible by the creation of a specific regulatory framework by European regulatory
发表于 2025-3-22 09:07:57 | 显示全部楼层
Immunogenicity,ors influencing immunogenicity—structural, linked to impurities and other production contaminants, factors linked to the medicine’s formulation, or linked to patients and treatment dependant—are studied in that chapter, as well as their consequences in regulatory terms.
发表于 2025-3-22 12:59:13 | 显示全部楼层
Substitution and Interchangeability,n of biosimilars is centralised as for reference products, the issue of substitution remains the specific field of the European Community Member States. In this chapter is described the French regulatory position—that does not allow the substitution of a reference biological product by a biosimilar,
发表于 2025-3-22 19:46:14 | 显示全部楼层
发表于 2025-3-22 23:55:51 | 显示全部楼层
发表于 2025-3-23 02:11:49 | 显示全部楼层
Wouter van Toll,Arjan Egges,Jeroen D. Fokkerarket in value), payers’ (significant savings expected for all parties), at last doctors and pharmacists’. How costs are established, what savings may be expected, is there a liability specific to biosimilars? In this chapter, a quick comparative view of European and American approaches and the concept of interchangeability.
发表于 2025-3-23 08:36:42 | 显示全部楼层
Jean-Louis Prugnaud,Jean-Hugues TrouvinAnalysis of the complete legal and regulatory framework.Approach of the context of copies of biology and biotechnology drugs.Details the registration conditions.Analysis of these drugs’ marketing (dru
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-7-6 16:58
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表